A 2023 JAMA Psilocybin Trial: Outcomes, Support, and Limits

Written by Psychedelic Stock Picks Editorial TeamNovember 8, 2026Clinical Trials1 min read

Key takeaways

The trial enrolled 104 adults and included psychological support.
Reported outcomes extended to day 43.
No serious adverse events in a trial is not proof of universal safety.

A randomized trial published in JAMA in 2023 compared single-dose psilocybin with niacin, both with psychological support, in adults with major depressive disorder. Its design and follow-up are essential context.

The research setting

Raison and colleagues studied 104 adults in a phase 2 randomized double-blind trial. Participants received the assigned intervention within a research framework that included psychological support.

The study did not examine unsupervised use or establish the effect of the compound apart from that framework. Descriptions that omit the support component leave out part of the studied intervention.

The measured results

The psilocybin group showed greater reductions in MADRS depression scores at day eight and day 43, as well as improvement in the reported disability measure at day 43. These are the outcomes and time points described in the publication.

A measured average difference is not a promise that every patient responds. It also does not establish how outcomes would look over a substantially longer period.

Boundaries of the evidence

Follow-up in the reported trial extended to day 43, and niacin served as the control. Masking deserves consideration when experiences may differ between conditions.

The authors reported no serious adverse events in this study. That is useful information, but it is not equivalent to proving broad or long-term safety in other populations.

Separate the result from market interpretation

The article concerns an August 2023 clinical publication. It does not tell readers whether a particular security is attractive or what a future regulatory decision will be.

A company’s rights, costs, competition, and finances are separate questions. Our research-first guide keeps those questions distinct.

Sources and further reading

Explore our research resources for help checking original sources.

Investment information: This article is educational, not a recommendation to buy or sell any security. Investments can lose value, including the entire amount invested. Research findings are not investment-return forecasts.

The accompanying picture is an illustrative editorial image, not a photograph of the cited study or its participants.